PGCM
AMLX icon

Prescott Group Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Prescott Group Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-40,000
Closed -$1.48M – 167
2022
Q4 		$1.48M Buy
40,000
+4,996
+14% +$177K 0.32% 78
2022
Q3 		$985K Buy
+35,004
New +$873K 0.3% 79

Other funds holding AMLX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Prescott Group Capital Management's AMLX Position: Q1 2023 in Review

Prescott Group Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2023, closing a stake of 40,000 shares — an estimated $1.48M sold.

Prescott Group Capital Management first reported a position in AMLX in Q3 2022 and held it in 2 quarters. The position peaked at $1.48M in Q4 2022. 147 funds tracked by Wall St. Rank hold AMLX as of Q1 2023.

  • Prescott Group Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Prescott Group Capital Management sold 40,000 Amylyx Pharmaceuticals shares in Q1 2023, an estimated $1.48M.
  • Prescott Group Capital Management first reported a position in Amylyx Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Prescott Group Capital Management's Amylyx Pharmaceuticals position peaked at $1.48M in Q4 2022.
  • 147 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2023.

Based on Prescott Group Capital Management's 13F filing for Q1 2023, filed 10 May 2023.